Document is current
Any future updates will be listed below
-
Authors
Spruijt, Melle A. https://orcid.org/0000-0001-6509-8270
Klerkx, Wenche M. https://orcid.org/0000-0002-0406-4760
Notten, Kim https://orcid.org/0000-0002-9107-4974
van Eijndhoven, Hugo https://orcid.org/0000-0001-6118-5676
Speksnijder, Leonie https://orcid.org/0000-0002-5768-7523
Kerkhof, Manon H. https://orcid.org/0000-0001-9986-763X
Kluivers, Kirsten B. https://orcid.org/0000-0002-4681-4304
-
Funding
Funding for this research was provided by:
St. Antonius Ziekenhuis
Isala Hospital
Allergan Foundation
- License Information
-
More Information
Article History
Received: 13 March 2026
Accepted: 20 June 2026
First Online: 16 July 2026
Declarations
Ethical Approval: This study, in combination with our RCT, was approved by the medical ethics committee of Arnhem-Nijmegen (ID: 2017–3130) and all local ethical committees in accordance with the Declaration of Helsinki. The study was registered at the European Union Drug Regulating Authorities Clinical Trials Database (2017–001296-23).
Conflicts of interest: Melle A Spruijt: No conflict of interest.Wenche M Klerkx: Member Dutch Urogynaecology board and Member Dutch Implant registration Committee. Both unpaid.Kim Notten: PI Dutch grant PPP allowance. Patent owner (publication number WO 2021/224332).Hugo van Eijndhoven: No conflict of interest.Leonie Speksnijder-de Jong: NPI (Dutch Institute for Postgraduate Education in Physiotherapy): Teaching activities for postgraduate physiotherapists.Avans University of Applied Sciences: Expert lecture on gynecology for physiotherapists in training. National Symposium for Pelvic Physiotherapists: Presentation on urogynecology at the national symposium.Manon H. Kerkhof: Astellas Pharma Europe Ltd.: Consultancy board with two steeringgroup meetings. Titus health Care speaker congress.Kirsten B. Kluivers: No conflict of interest.
